LT2892535T - Adjuvantinis vėžio gydymo būdas - Google Patents

Adjuvantinis vėžio gydymo būdas

Info

Publication number: LT2892535T
Authority: LT; Lithuania
Prior art keywords: cancer treatment; adjuvant cancer; adjuvant; treatment; cancer
Prior art date: 2012-09-04

Application number

LTEPPCT/US2013/057432T

Other languages

English (en)

Lithuanian (lt)

Inventor

Sylvie Laquerre

Peter F. Lebowitz

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-04

Filing date

2013-08-30

Publication date

2021-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2892535(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-30 Application filed by Novartis Ag filed Critical Novartis Ag

2021-12-10 Publication of LT2892535T publication Critical patent/LT2892535T/lt

Links

206010028980 Neoplasm Diseases 0.000 title 1
239000002671 adjuvant Substances 0.000 title 1
201000011510 cancer Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)

LTEPPCT/US2013/057432T 2012-09-04 2013-08-30 Adjuvantinis vėžio gydymo būdas LT2892535T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261696375P	2012-09-04	2012-09-04
PCT/US2013/057432 WO2014039375A1 (en)	2012-09-04	2013-08-30	Method of adjuvant cancer treatment

Publications (1)

Publication Number	Publication Date
LT2892535T true LT2892535T (lt)	2021-12-10

Family

ID=50237545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2013/057432T LT2892535T (lt)	2012-09-04	2013-08-30	Adjuvantinis vėžio gydymo būdas

Country Status (20)

Country	Link
US (6)	US20150216868A1 (2)
EP (2)	EP3981408A1 (2)
JP (3)	JP2015527374A (2)
KR (1)	KR102134585B1 (2)
CN (2)	CN104582706A (2)
AU (2)	AU2013313050A1 (2)
BR (1)	BR112015004578A2 (2)
CA (1)	CA2882437C (2)
CY (1)	CY1124812T1 (2)
DK (1)	DK2892535T3 (2)
ES (1)	ES2900825T3 (2)
HR (1)	HRP20211817T1 (2)
HU (1)	HUE056646T2 (2)
IN (1)	IN2015KN00449A (2)
LT (1)	LT2892535T (2)
PL (1)	PL2892535T3 (2)
PT (1)	PT2892535T (2)
RU (1)	RU2640180C2 (2)
SI (1)	SI2892535T1 (2)
WO (1)	WO2014039375A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104582706A (zh)	2012-09-04	2015-04-29	葛兰素史克有限责任公司	辅助癌症治疗的方法
ES2660989T3 (es)	2013-12-28	2018-03-27	Guardant Health, Inc.	Métodos y sistemas para detectar variantes genéticas
AU2017329090B9 (en)	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en)	2017-05-02	2018-11-08	Novartis Ag	Combination therapy
US11890286B2 (en) *	2018-04-17	2024-02-06	The University Of Chicago	Methods and compositions for treating cancer
CN109106893B (zh) *	2018-11-12	2021-04-20	上海市中西医结合医院	一种调节肠道屏障功能的中药复方制剂及其制备方法
EP3969449B1 (en)	2019-05-13	2025-02-12	Novartis AG	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN118767143A (zh) *	2019-12-12	2024-10-15	听治疗有限责任公司	用于预防和治疗听力损失的组合物和方法
WO2023105286A1 (en)	2021-12-06	2023-06-15	My Personal Therapeutics Ltd	A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1761528T1 (sl) *	2004-06-11	2008-06-30	Japan Tobacco Inc	5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
KR20070114753A (ko) *	2005-02-18	2007-12-04	아브락시스 바이오사이언스 인크.	치료제의 조합 및 투여 방식, 및 조합 요법
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
HUE067723T2 (hu) *	2009-10-16	2024-11-28	Novartis Ag	MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció
US20130004481A1 (en) *	2011-01-12	2013-01-03	Boehringer Ingelheim International Gmbh	Anticancer therapy
CN104582706A (zh)	2012-09-04	2015-04-29	葛兰素史克有限责任公司	辅助癌症治疗的方法

2013
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active Active
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN107308164A (zh)	2017-11-03
HUE056646T2 (hu)	2022-02-28
US20150216868A1 (en)	2015-08-06
WO2014039375A1 (en)	2014-03-13
JP2018058859A (ja)	2018-04-12
KR102134585B1 (ko)	2020-07-17
EP2892535A4 (en)	2016-04-13
US10869869B2 (en)	2020-12-22
JP2015527374A (ja)	2015-09-17
PL2892535T3 (pl)	2022-01-31
US20200054641A1 (en)	2020-02-20
US20230330091A1 (en)	2023-10-19
AU2013313050A1 (en)	2015-03-26
HRP20211817T1 (hr)	2022-03-04
RU2015105821A (ru)	2016-10-20
PT2892535T (pt)	2021-12-15
EP2892535B1 (en)	2021-09-22
ES2900825T3 (es)	2022-03-18
BR112015004578A2 (pt)	2017-07-04
JP2019142899A (ja)	2019-08-29
RU2640180C2 (ru)	2017-12-26
EP3981408A1 (en)	2022-04-13
HK1206642A1 (en)	2016-01-15
SI2892535T1 (sl)	2022-01-31
CN104582706A (zh)	2015-04-29
DK2892535T3 (da)	2022-01-03
CA2882437A1 (en)	2014-03-13
US20170202842A1 (en)	2017-07-20
JP6684941B2 (ja)	2020-04-22
CA2882437C (en)	2021-03-02
EP2892535A1 (en)	2015-07-15
US20210060021A1 (en)	2021-03-04
CY1124812T1 (el)	2022-11-25
AU2016244279B2 (en)	2018-01-04
US20180338979A1 (en)	2018-11-29
KR20150047619A (ko)	2015-05-04
AU2016244279A1 (en)	2016-11-03
JP6511117B2 (ja)	2019-05-15
IN2015KN00449A (2)	2015-07-17

Publication	Publication Date	Title
IL288181A (en)	2022-01-01	Cancer treatment methods
IL237791B (en)	2020-10-29	A method for treating cancer
SG11201503893RA (en)	2015-06-29	Method of treating cancer
SG11201501653RA (en)	2015-04-29	Methods for the treatment of locally advanced breast cancer
IL232890A0 (en)	2014-07-31	Immunogenic therapy for cancer
IL232530A0 (en)	2014-06-30	Combined cancer treatment
EP2895206A4 (en)	2016-05-04	METHOD FOR TREATING CARCINOMA
IL228430A0 (en)	2013-12-31	Cancer treatment
SI2892535T1 (sl)	2022-01-31	Postopek adjuvantnega zdravljenja raka
EP2903644A4 (en)	2016-03-09	TREATMENT OF CANCER
GB201217892D0 (en)	2012-11-21	Treatment of cancer
IL237229A0 (en)	2015-04-30	Methods of treating cancer using lipoplatin
GB201217890D0 (en)	2012-11-21	Treatment of cancer
IL232266A0 (en)	2014-06-30	Cancer treatment methods
GB201208296D0 (en)	2012-06-20	Treatment of cancer
GB201121783D0 (en)	2012-02-01	Treatment of cancer
GB201221032D0 (en)	2013-01-09	Method of treatment
GB201207894D0 (en)	2012-06-20	Method of treatment
GB201221118D0 (en)	2013-01-09	Methods of treatment
GB201216748D0 (en)	2012-10-31	Methods of treatment
GB201216740D0 (en)	2012-10-31	Methods of treatment
AU2012905667A0 (en)	2013-01-17	Vaccines for treatment of cancer
GB201206330D0 (en)	2012-05-23	Methods of treatment
GB201206326D0 (en)	2012-05-23	Methods of treatment
GB201206325D0 (en)	2012-05-23	Methods of treatment